Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

María S. Soengas, Paola Capodieci, David Polsky, Jaume Mora, Manel Esteller, Ximena Opitz-Araya, Richard McCombie, James G. Herman, William L. Gerald, Yuri A. Lazebnik, Carlos Cordón-Cardó, Scott W. Lowe

Research output: Contribution to journalArticlepeer-review

870 Scopus citations


Metastatic melanoma is a deadly cancer that fails to respond to conventional chemotherapy and is poorly understood at the molecular level1. p53 mutations often occur in aggressive and chemoresistant cancers but are rarely observe in melanoma1.2. Here we show that metastatic melanomas often lose Apaf-1,a cell-death effector that acts with cytocrhome c and caspase-9 to mediate p53-dependent apoptosis3. Loss of Apaf-1 expression is accompanied by allelic loss in metastatic melanomas, but can be recovered in melanoma cell lines by treatment with the methylation inhibitor 5-aza-2' -deoxycytidine (5aza2dC). Apaf-1-negative melanomas are invariably chemoresistant and are unable to execute a typical apoptotic programme in response to p53 activation. Restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment markedly enhances chemosensivity and rescues the apoptotic defects associated with Apaf-1 loss. We conclude that Apaf-1 is inactivated in matastatic melanomas, which leads to defects in the execution of apoptotic cell death. Apaf-1 loss may contribute to the low frequency of p53 mutations observed in this highly chemoresistant tumour type.

Original languageEnglish
Pages (from-to)207-211
Number of pages5
Issue number6817
StatePublished - 11 Jan 2001
Externally publishedYes


Dive into the research topics of 'Inactivation of the apoptosis effector Apaf-1 in malignant melanoma'. Together they form a unique fingerprint.

Cite this